Israel's Sensible Medical has picked up a reported $20 million to fund development of its noninvasive lung fluid monitor, closing a round led by global device giant Boston Scientific.
Boehringer Ingelheim has chosen an antibody therapeutic candidate discovered by Rockville, MD-based MacroGenics for preclinical development.
The U.S. coronary stent market is already crowded and competitive, but Israel's ITGI Medical sees room for at least one more player. It recently inked a deal with Vascular Solutions that helps propel the regulatory process and then marketing for its pericardium-covered stent after getting it approved for use.
Cancer drug developer Cel-Sci ($CVM) wants at least $50 million in damages in from ex-CRO partner inVentiv Health, claiming breach of contract and fraud.
As regulators the world over clamp down on biologics development, Covance has struck up a partnership with Pathoquest to offer next-generation sequencing-based tests for biotherapeutics.
J&J has spent hundreds of millions of dollars in a so-far failed effort to develop a late-stage biologic that could be used to treat Alzheimer's. And it's now prepared to spend hundreds of millions more as it goes back to the drawing board to explore the molecular underpinnings of the disease in an attempt to find new therapies that promise to thwart the disease before it cripples the brain.
The number of failures in the Alzheimer's drug research field has been piling up disproportionately compared to successes in recent years, and the New York Academy of Sciences is hoping to change that by proposing a more streamlined, efficient path for Alzheimer's drug development.
Roche's Ventana Medical Systems will pair off with drug developer Incyte to create companion diagnostic tests designed to work with the company's cancer drugs. Once again, the personalized medicine movement moves forward.
Fresh off closing a $42 million funding round, CVRx is partnering up with investor DaVita, joining forces to speed up development of the company's nerve-stimulating hypertension treatment.
When Pfizer first let slip that it struck a deal to collaborate with Eli Lilly on the high-risk anti-NGF pain drug tanezumab, the news was delivered without any of the usual deal terms.